Double versus standard dose of tamsulosin with solifenacin for management of ureteral stent related symptoms.

Background: Ureteral stents are commonly used to ensure adequate drainage of the upper urinary tract in the presence, or anticipated occurrence, of ureteral obstruction. However, stent-related symptoms are frequent and represent a significant source of morbidity. Although several pharmacological treatment options are currently available, symptom relief remains often incomplete. In an effort to achieve better control of stent-related symptoms, we evaluated the efficacy of dose doubling in two commonly used drug combinations that have demonstrated symptomatic benefits in this context. Objective: To evaluate the efficacy of a double dose of solifenacin and tamsulosin compared to the standard dose of the same agents in alleviating stent-related symptoms. Patients and methods: A randomized clinical trial was conducted involving 64 Egyptian patients recruited from the outpatient clinic and inpatient services of the Urology Department at Ain Shams University Hospital over a six-month period. Results: After two weeks of treatment, the double dose of tamsulosin and solifenacin was significantly more effective in reducing stent-related symptoms compared to the standard dose. A statistically significant difference in symptom scores was observed between the double-dose and standard-dose groups. Side effects were more frequent in the double-dose group, with retrograde ejaculation and dry mouth occurring at significantly higher rates. Conclusion: The combination of tamsulosin and solifenacin is effective in alleviating stent-related symptoms. In patients who continue to experience symptoms despite standard-dose therapy, doubling the dose of both agents may offer additional symptomatic relief, albeit with a higher incidence of temporary and manageable side effects.